Castle Biosciences, Inc. (CSTL) Cash Flow Statement
Castle Biosciences, Inc. (CSTL) generated $42.6M of operating cash flow over the twelve months to 2026-06-30, spent $43.1M on capital expenditure and had free cash flow of -$489000, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CSTLCastle Biosciences, Inc.Follow CSTL — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 7.0 | 9.9 | -19.0 | -41.7 | -5.6 | 64.9 | 64.3 | 42.6 | |
| Capital expenditure | 0.9 | 4.8 | 3.5 | 5.6 | 13.6 | 28.3 | 36.0 | -43.1 | |
| Free cash flow | 6.1 | 5.1 | -22.5 | -47.3 | -19.2 | 36.5 | 28.3 | -0.5 | |
| Stock-based compensation | 1.2 | 8.3 | 21.7 | 36.3 | 51.2 | 50.3 | 45.9 | — |
USD millions · SEC XBRL
Castle Biosciences, Inc. — questions
- What is Castle Biosciences, Inc.'s operating cash flow?
- $42.6M over the twelve months to 2026-06-30.
- How much does Castle Biosciences, Inc. spend on capital expenditure?
- $43.1M over the twelve months to 2026-06-30.
- What is Castle Biosciences, Inc.'s free cash flow?
- -$489000 over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Castle Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.